Which Billionaire Fund Manager Likes Horizon Pharma?

FARALLON CAPITALIn a 13G filing last week, billionaire fund manager Thomas Steyer of Farallon Capital Management announced that his firm now had a 5.4% ownership stake in Horizon Pharma Inc. (NASDAQ:HZNP)—buying almost 1.9 million shares. Steyer founded Farallon in 1986 and previously worked for Goldman Sachs and Morgan Stanley.

The Farallon news come in conjunction with other recent reports that notable pharmaceutical investors Tang Capital and Sutter Hill Ventures took a 9.9% and 6.1% stake, respectively, in Horizon Pharma. Tang Capital is also a large shareholder in Penwest Pharmaceuticals and A.P. Pharma, and Sutter Hill is a notable investor in Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), which is up almost 500% year to date.

The company announced an agreement with Merck earlier this year to co-develop and commercialize TH-302—a hypoxia-targeted drug. Threshold is set to receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012. Next year EPS for the company is still in the red, with estimated 2013 EPS of negative $0.21, but this would still mean a 87% gain from the previous year.

The Horizon stake represents a new position for Farallon, which took positions in other biopharmaceutical companies during 2Q, Amylin Pharmaceuticals and Merrimack Pharmaceuticals Inc (NASDAQ:MACK) among them. Merrimack has a focus on developing medicines to treat serious diseases, with a particular focus on cancer. Up 50% year to date, the company is also like the other pharma companies mentioned, operating at a negative EPS. Next year EPS is expected to be negative $0.91, but up 50% year over year.

Horizon is a biopharmaceutical company, developing medicines targeting arthritis, but is flat year to date. Horizon’s 2Q results put the company’s revenues up to $3.8 million, compared to the same quarter in 2011 at $1.3 million. As well, the company continued its string of net losses, posting a net loss of $22.8 million, or negative EPS of $0.68.

In July, Horizon announced FDA approval for RAYOS, a drug used to treat a broad range of diseases including rheumatoid arthritis and polymyalgia rheumatic, among others. The company still has a long way to go before offering the drug, and is still very speculative. Running tight on liquidity, Horizon recently announced a move to raise more capital that will allow it to offer as many as 36.9 million new shares, compared to the near 34 million shares that are currently outstanding.

A couple key competitors for Horizon include Par Pharmaceutical Companies, Inc. (NYSE:PRX) and Perrigo Company (NASDAQ:PRGO). Both of these companies are a bit bigger than Horizon. Perrigo has beat EPS estimates the last four quarters and is expected to grow next quarter EPS by 18% from the same quarter last year. Perrigo has also decided to try its hand in the animal care market, purchasing Sergeant’s Pet Care Products for $285 million last week. This could be a key move for Perrigo to enter the $8 billion pet care industry, as it is already expected to add $0.12 to EPS next quarter.

Par missed last quarter estimates by 250%, but in July, the private equity firm TPG announced plans to purchase Par for $1.9 billion. The deal, valued at $50 per share, pushed Par’s stock up 50% year to date. Even with the share price spike, the company trades at a forward P/E of 14, much less than its trailing P/E of 22.

As far as Horizon, the company should be considered a speculative play, but has attracted some large interest from other notable pharma investors, with Farallon, Tang and Sutter now collectively owning over 20% of its outstanding shares. Also worth noting is the string of insider purchases between $3.49-$3.59 by a company director, where the company currently trades around $3.50. For a complete look at the insider and hedge fund sentiment surrounding Horizon Pharma, continue reading here.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!